

SHORT
COMMUNICATIONS

Selective Deacetylation of 11 α -Hydroxyestrone 17-Oxime Triacetate in the Synthesis of 11 α -Acetoxyestrone

L.E. Golubovskaya, T.A. Titova, and V.M. Pzheznikov

Institute of Experimental Endocrinology at Endocrinological Scientific Center, Russian Academy of Medical Sciences,
Moscow, 117036 Russia
e-mail: sterlabenc@mtu-net.ru

Received July 22, 2005

DOI: 10.1134/S1070428002120242


We formerly reported on the synthesis of antitumor steroids in the series of 17 α -ethynylestradiol [1, 2]. The presence in their structure of a fragment containing a bis(β -chloroethyl)amino group in the position 3 and an 11 α -acyloxy-substituent provides a valuable combination of antiestrogen and cytotoxic properties in these compounds.

Aiming at the search of new analogs and planning to study the dependence of the activity on the structure of this type steroids we undertook the synthesis of similar compounds in the estrone series.

11 α -Acetoxyestrone (VII) is an acceptable synthons for their preparation, and this study is dedicated to its synthesis. The main synthetic goal, the introduction of

a hydroxy group into position 11 α of steroid with an aromatic A ring, might be solved by the previously used procedure [3, 4] involving two principal stages: oxidative nitration with the cerium ammonium nitrate, and reduction with NaBH₄. Before the reduction with the sodium borohydride it was necessary to protect the keto group of estrone (I) acetate. The best protection proved to be the oximation [5]. The reduction of compound III occurred stereoselectively, and the yield of oxime IV was 79%. The ¹H NMR spectrum did not reveal the presence of its 9 β -epimer, whereas at the similar reduction of 17-ethyleneketal formed up to 15% of 9 β -steroid.

We failed to perform regioselective acetylation of oxime IV either with Cu(OAc)₂ [6] or by transesterific-



R = O (II), NOH (III); R = R' = H (IV), Ac (V); R = H, R' = Ac (VI).

ation with ethyl acetate in the presence of *p*-TsOH [7]. But its triacetate **V** turned out to be capable of regioselective transformations. At treatment with pyruvic acid occurred both the removal of protection and deacetylation in position C³ resulting in 80% yield of the target 11 α -acetoxyestrone (**VII**). The hydrolysis of triacetate **V** occurred also regioselectively with retention of only 11 α -acetoxy group. The yield of monoacetate **VI** was 95%.

17-Hydroxyiminoestra-1,3,5(10)-triene-3,11 α -diol triacetate (V). To a solution of 2.0 g (4.95 mmol) of oxime **III** [5] in 50 ml of ethanol was added by portions at stirring 0.9 g (23.7 mmol) of NaBH₄. The dispersion was stirred for 3.5 h at 20°C, diluted with water, acidified with 10% HCl till pH 3–4, filtered from the precipitate of salts, the filtrate was evaporated by 1/3. The separated precipitate of oxime **IV** was dissolved in ethyl acetate, dried with MgSO₄, and evaporated to obtain 1.18 g (90%) of crystalline 17-oximinoestra-1,3,5(10)-triene-3,11 α -diol (**IV**), mp 217–220°C, [α]_D –(36 ± 4°). IR spectrum, ν , cm⁻¹: 3375–3400 (OH), 1707 (C=N), 1610, 1580, 1500 (C=C_{arom}), 920 (N–O). ¹H NMR spectrum (C₅D₅N), δ , ppm: 1.0 s (3H, 18-CH₃), 4.56 t.d (1H, C¹¹H, *J* 10 and 5 Hz), 7.06 m (2H, C²H and C⁴H), 8.66 d (1H, C¹H, *J* 8.5 Hz).

A solution of 0.88 g of oxime **IV** in 8 ml of a mixture acetic anhydride–pyridine, 1:1, was maintained for 16 h at 20°C, and then diluted with water. The precipitate of triacetate **V** was dissolved in chloroform, dried over MgSO₄, and the solvent was evaporated to furnish 1.2 g of compound **V**, mp 165–167°C (from a mixture of acetone with ether), [α]_D –(110 ± 10°). UV spectrum: λ_{\max} 274 nm (log ϵ 2.93). IR spectrum, ν , cm⁻¹: 1765, 1730, 1225 (OAC), 1490 (C=C_{arom}), 925 (N–O). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.05 s (3H, 18-CH₃), 2.06 s (3H, 11-OAC), 2.16 s (3H, N–OAc), 2.28 s (3H, 3-OAc), 5.49 t.d (1H, C¹¹H, *J* 9.8 and 5 Hz), 6.9 m (2H, C²H and C⁴H), 7.09 d (1H, C¹H, *J* 9 Hz). Found, %: C 67.11; H 6.63, N 3.50. C₂₄H₂₉NO₆. Calculated, %: C 67.43; H 6.84; N 3.28.

11 α -Acetoxy 17-hydroxyiminoestra -1,3,5(10)-trien-3-ol (VI). A solution of 330 mg of triacetate **V** in 7 ml of methanol was stirred with 1 ml of triethylamine for 5 h at 20°C, then the mixture was evaporated, and the dark-yellow oily residue was dissolved in a mixture benzene–chloroform, 2:1. The solution was passed through 10 g of silica gel, and on evaporating the filtrate the residue was ground with ether to obtain 252 mg (95%) of compound **VI**, mp 210–213°C (from a mixture ethyl acetate–hexane), [α]_D –(139 ± 10°). UV spectrum: λ_{\max}

280 nm (log ϵ 3.39). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.97 s, 2.06 s, 5.44 t.d, 6.58 m, 6.88 d. Found, %: C 69.67; H 7.08; N 4.26. C₂₀H₂₅NO₄. Calculated, %: C 69.95; H 7.34; N 4.08.

11 α -Acetoxy-3-hydroxyestra-1,3,5(10)-trien-17-one (VII). A solution of 260 mg (0.61 mmol) of triacetate **V** and 180 mg (2.04 mmol) of pyruvic acid in 3.8 ml of 70% acetic acid was heated under argon at 70°C for 20 h. The solution turned yellow; it was diluted with 25 ml of water, the separated precipitate was dissolved in chloroform, and the solution was passed through 10 g of silica gel. The column was additionally washed with 20 ml of chloroform, and on evaporating the solvent we obtained 160 mg (80%) of compound **VII**, mp 261–263°C, [α]_D –(66 ± 4°), *R*_f 0.42. UV spectrum: λ_{\max} 280 nm (log ϵ 3.32). IR spectrum, cm⁻¹: 3400, 1735, 1697 (CO), 1605, 1500, 1265. ¹H NMR spectrum (CDCl₃), δ , ppm: 0.94 s, 2.07 s, 5.38 t.d, 6.59 m, 6.89 d. Found, %: C 69.92; H 7.12. C₂₀H₂₄O₄. Calculated, %: C 73.15; H 7.36.

Melting points were determined on the Boëtius heating block. The optical rotation was measured on a polarimeter Polamat from solutions in CHCl₃. UV spectra were recorded on a spectrophotometer Specord UV-Vis in ethanol solutions, IR spectra, on Specord 75 IR instrument from KBr pellets. ¹H NMR spectra were registered on a spectrometer Bruker DPX-400, internal reference TMS. TLC analysis was carried out on Silufol-254 plates in a system hexane–ethyl acetate, 3:2.

The study was carried out under the financial support of the Russian Foundation for Basic Research (grant no. 04-03-32037).

REFERENCES

- Rzheznikov, V.M., Golubovskaya, L.E., Minailova, O.N., Cmironova, Z.S., Sushinina, L.P., Titova, T.A., and Tolkachev, V.N., RF Patent 2139292, 1998; *Byull. Izobr.*, 1999, no. 28.
- Smirnova, Z.S., Osetrova, I.P., Rzheznikov, V.M., Sushinina, L.P., and Tolkachev, V.N., Abstracts of Papers, *XVI Int. Cancer Congress*, New Delhi, 1994, p. 301.
- Rzheznikov, V.M., *Bioorg. Khim.*, 1991, vol. 17, p. 1002.
- Golubovskaya, L.E., Minailova, O.N., and Rzheznikov, V.M., Abstracts of Papers, *11th Int. Symp. on the Chemistry of Natural Compounds*, Eskisehir, Turkey, 1996, p. 138.
- Rzheznikov, V.M., Golubovskaya, L.E., Minailova, O.N., Osetrova, I.P., and Smirnova, Z.S., *Khim.-Farm.Zh.*, 2003, vol. 37, p. 12.
- Wu, Y. and Blackwell, L.F., *Steroids*, 1993, vol. 58, p. 452.
- Kuhajda, K., Kandrac, J., Cirin-Novta, V., and Mikovic, D., *Collect. Czech. Chem. Commun.*, 1996, vol. 61, p. 1073